Discovery of a Highly Potent and Selective Small-Molecule Inhibitor of In Vivo Anaerobic Choline Metabolism by Human Gut Bacteria
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c01451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Mariell Pettersson und 25 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43…. Hauptthemen laut MEDLINE: Choline, Enzyme Inhibitors, Gastrointestinal Microbiome, Small Molecule Libraries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Trimethylamine (TMA) Lyase is an enzyme expressed in human gut bacteria that plays a pivotal role in the formation of trimethylamine oxide (TMAO), a metabolite implicated in the development of heart failure. Here, we describe a strategy to design covalent inhibitors targeting the active site thiyl radical involved in the catalytic cycle of the enzyme under anaerobic conditions. This strategy led to the discovery of 7, a previously unreported highly potent and selective inhibitor of TMA Lyase. When dosed orally to rats, 7 shows a significant reduction of circulating TMAO levels and, importantly, demonstrates inhibition of TMAO generated from a human microbiome when profiled in a human fecal mouse transplant model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 83, Sweden.
- Protein, Structure and Biophysics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 83, Sweden.
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 83, Sweden.
- Bioinformatics, Research and Early Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland 20878, United States.
- Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 83, Sweden.
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland 20878, United States.
ORCID-Profile: Mariell Pettersson, Giuseppina La Sala, Anna Vildhede, Dušan Petrović, Marta Szydlowska, Margareta Ek, Tove Sjögren
Zitieren
APA
Pettersson, M., La Sala, G., Gunnarsson, A., Vildhede, A., Sparklin, B., Holm, B., Petrović, D., Lasky, G., Turick, S., Szydlowska, M., Gopalakrishnan, V., Bake, T., Petersen, J., Brånalt, J., Westerlund, K., Taillefer, M., Henricsson, M., Ek, M., Warrener, P., …, & Liddle, J. (2026). Discovery of a Highly Potent and Selective Small-Molecule Inhibitor of In Vivo Anaerobic Choline Metabolism by Human Gut Bacteria. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01451
Vancouver
Pettersson M, La Sala G, Gunnarsson A, Vildhede A, Sparklin B, Holm B, et al. Discovery of a Highly Potent and Selective Small-Molecule Inhibitor of In Vivo Anaerobic Choline Metabolism by Human Gut Bacteria. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c01451
BibTeX
@article{Pettersson2026,
author = {Pettersson, Mariell and La Sala, Giuseppina and Gunnarsson, Anders and Vildhede, Anna and Sparklin, Ben and Holm, Björn and Petrović, Dušan and Lasky, Ginger and Turick, Scott and Szydlowska, Marta and Gopalakrishnan, Vancheswaran and Bake, Tina and Petersen, Jens and Brånalt, Jonas and Westerlund, Kristina and Taillefer, Marcel and Henricsson, Marcus and Ek, Margareta and Warrener, Paul and Roth, Robert and Cohen, Taylor and Sjögren, Tove and Fahlander, Ulf and Jurva, Ulrik and Morias, Yannick and Liddle, John},
title = {Discovery of a Highly Potent and Selective Small-Molecule Inhibitor of In Vivo Anaerobic Choline Metabolism by Human Gut Bacteria},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c01451}
}
EUVIMED